{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T03:21:28Z","timestamp":1789528888495,"version":"build-2803163510"},"reference-count":32,"publisher":"American Association for Cancer Research (AACR)","issue":"9","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Although the BCR\/ABL tyrosine kinase inhibitor imatinib is highly effective for treatment of chronic myelogenous leukemia and Philadelphia chromosome\u2013positive (Ph+) acute lymphoblastic leukemia, relapse with emerging imatinib resistance mutations in the BCR\/ABL kinase domain poses a significant problem. Here, we show that the multikinase inhibitor sorafenib inhibits proliferation and induces apoptosis at much lower concentrations in Ton.B210 cells when driven by inducibly expressed BCR\/ABL than when driven by interleukin-3. The increased sensitivity to sorafenib was also observed in cells inducibly expressing BCR\/ABL with the imatinib-resistant E255K or T315I mutation. Sorafenib-induced apoptosis in these cells and Ph+ leukemic cells was synergistically enhanced by rottlerin, bortezomib, or ABT-737 and inhibited by the pan-caspase inhibitor BOC-d-fmk or the overexpression of Bcl-XL. It was further revealed that sorafenib activates Bax and caspase-3 and reduces mitochondrial membrane potential specifically in BCR\/ABL\u2013driven cells. Sorafenib also inhibited BCR\/ABL\u2013induced tyrosine phosphorylation of its cellular substrates and its autophosphorylation in Ton.B210. It was finally shown that sorafenib inhibits the kinase activity of BCR\/ABL as well as its E255K and T315I mutants in in vitro kinase assays. These results indicate that sorafenib induces apoptosis of BCR\/ABL\u2013expressing cells, at least partly, by inhibiting BCR\/ABL to activate the mitochondria-mediated apoptotic pathway. Thus, sorafenib may provide an effective therapeutic measure to treat Ph+ leukemias, particularly those expressing the T315I mutant, which is totally resistant to imatinib and the second generation BCR\/ABL inhibitors. [Cancer Res 2009;69(9):3927\u201336]<\/jats:p>","DOI":"10.1158\/0008-5472.can-08-2978","type":"journal-article","created":{"date-parts":[[2009,4,15]],"date-time":"2009-04-15T00:26:42Z","timestamp":1239755202000},"page":"3927-3936","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Sorafenib Induces Apoptosis Specifically in Cells Expressing BCR\/ABL by Inhibiting Its Kinase Activity to Activate the Intrinsic Mitochondrial Pathway"],"prefix":"10.1158","volume":"69","author":[{"given":"Tetsuya","family":"Kurosu","sequence":"first","affiliation":[{"name":"1Department of Hematology, Graduate School of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Ohki","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Graduate School of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Wu","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Graduate School of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kagechika","sequence":"additional","affiliation":[{"name":"2School of Biomedical Science, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Miura","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Graduate School of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2009,4,30]]},"reference":[{"key":"2022061701492614700_B1","doi-asserted-by":"crossref","unstructured":"Goldman JM, Melo JV. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med\u20082003; 349: 1451\u201364.","DOI":"10.1056\/NEJMra020777"},{"key":"2022061701492614700_B2","doi-asserted-by":"crossref","unstructured":"Wong S, Witte ON. The BCR-ABL story: bench to bedside and back. Annu Rev Immunol\u20082004; 22: 247\u2013306.","DOI":"10.1146\/annurev.immunol.22.012703.104753"},{"key":"2022061701492614700_B3","doi-asserted-by":"crossref","unstructured":"Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood\u20082005; 105: 2640\u201353.","DOI":"10.1182\/blood-2004-08-3097"},{"key":"2022061701492614700_B4","doi-asserted-by":"crossref","unstructured":"O'Hare T, Corbin AS, Druker BJ. Targeted CML therapy: controlling drug resistance, seeking cure. Curr Opin Genet Dev\u20082006; 16: 92\u20139.","DOI":"10.1016\/j.gde.2005.11.002"},{"key":"2022061701492614700_B5","doi-asserted-by":"crossref","unstructured":"Yamamoto M, Kurosu T, Kakihana K, Mizuchi D, Miura O. The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR\/ABL fusion kinase. Biochem Biophys Res Commun\u20082004; 319: 1272\u20135.","DOI":"10.1016\/j.bbrc.2004.05.113"},{"key":"2022061701492614700_B6","doi-asserted-by":"crossref","unstructured":"Kurosu T, Tsuji K, Kida A, Koyama T, Yamamoto M, Miura O. Rottlerin synergistically enhances imatinib-induced apoptosis of BCR\/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-\u03b4. Oncogene\u20082007; 26: 2975\u201387.","DOI":"10.1038\/sj.onc.1210117"},{"key":"2022061701492614700_B7","doi-asserted-by":"crossref","unstructured":"Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer\u20082007; 7: 345\u201356.","DOI":"10.1038\/nrc2126"},{"key":"2022061701492614700_B8","doi-asserted-by":"crossref","unstructured":"Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib:a multikinase inhibitor for treating cancer. Nat Rev Drug Discov\u20082006; 5: 835\u201344.","DOI":"10.1038\/nrd2130"},{"key":"2022061701492614700_B9","doi-asserted-by":"crossref","unstructured":"Jin A, Kurosu T, Tsuji K, et al. BCR\/ABL and IL-3 activate Rap1 to stimulate the B-Raf\/MEK\/Erk and Akt signaling pathways and to regulate proliferation, apoptosis, and adhesion. Oncogene\u20082006; 25: 4332\u201340.","DOI":"10.1038\/sj.onc.1209459"},{"key":"2022061701492614700_B10","doi-asserted-by":"crossref","unstructured":"Auclair D, Miller D, Yatsula V, et al. Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia\u20082007; 21: 439\u201345.","DOI":"10.1038\/sj.leu.2404508"},{"key":"2022061701492614700_B11","doi-asserted-by":"crossref","unstructured":"Zhang W, Konopleva M, Shi YX, et al. Mutant FLT3:a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst\u20082008; 100: 184\u201398.","DOI":"10.1093\/jnci\/djm328"},{"key":"2022061701492614700_B12","doi-asserted-by":"crossref","unstructured":"Rahmani M, Davis EM, Bauer C, Dent P, Grant S. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem\u20082005; 280: 35217\u201327.","DOI":"10.1074\/jbc.M506551200"},{"key":"2022061701492614700_B13","doi-asserted-by":"crossref","unstructured":"Yu C, Bruzek LM, Meng XW, et al. The role of Mcl-1 down-regulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene\u20082005; 24: 6861\u20139.","DOI":"10.1038\/sj.onc.1208841"},{"key":"2022061701492614700_B14","doi-asserted-by":"crossref","unstructured":"Rahmani M, Davis EM, Crabtree TR, et al. The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol Cell Biol\u20082007; 27: 5499\u2013513.","DOI":"10.1128\/MCB.01080-06"},{"key":"2022061701492614700_B15","doi-asserted-by":"crossref","unstructured":"Rahmani M, Nguyen TK, Dent P, Grant S. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr\/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation. Mol Pharmacol\u20082007; 72: 788\u201395.","DOI":"10.1124\/mol.106.033308"},{"key":"2022061701492614700_B16","doi-asserted-by":"crossref","unstructured":"Klucher KM, Lopez DV, Daley GQ. Secondary mutation maintains the transformed state in BaF3 cells with inducible BCR\/ABL expression. Blood\u20081998; 91: 3927\u201334.","DOI":"10.1182\/blood.V91.10.3927"},{"key":"2022061701492614700_B17","doi-asserted-by":"crossref","unstructured":"Tohda S, Sakashita C, Fukuda T, Murakami N, Nara N. Establishment of a double Philadelphia chromosome-positive acute lymphoblastic leukemia-derived cell line, TMD5:effects of cytokines and differentiation inducers on growth of the cells. Leuk Res\u20081999; 23: 255\u201361.","DOI":"10.1016\/S0145-2126(98)00172-6"},{"key":"2022061701492614700_B18","doi-asserted-by":"crossref","unstructured":"Morita S, Kojima T, Kitamura T. Plat-E:an efficient and stable system for transient packaging of retroviruses. Gene Ther\u20082000; 7: 1063\u20136.","DOI":"10.1038\/sj.gt.3301206"},{"key":"2022061701492614700_B19","doi-asserted-by":"crossref","unstructured":"Chao DT, Linette GP, Boise LH, White LS, Thompson CB, Korsmeyer SJ. Bcl-XL and Bcl-2 repress a common pathway of cell death. J Exp Med\u20081995; 182: 821\u20138.","DOI":"10.1084\/jem.182.3.821"},{"key":"2022061701492614700_B20","doi-asserted-by":"crossref","unstructured":"Kitamura T, Koshino Y, Shibata F, et al. Retrovirus-mediated gene transfer and expression cloning:powerful tools in functional genomics. Exp Hematol\u20082003; 31: 1007\u201314.","DOI":"10.1016\/S0301-472X(03)00260-1"},{"key":"2022061701492614700_B21","doi-asserted-by":"crossref","unstructured":"Arai A, Kanda E, Nosaka Y, Miyasaka N, Miura O. CrkL is recruited through its SH2 domain to the erythropoietin receptor and plays a role in Lyn-mediated receptor signaling. J Biol Chem\u20082001; 276: 33282\u201390.","DOI":"10.1074\/jbc.M102924200"},{"key":"2022061701492614700_B22","doi-asserted-by":"crossref","unstructured":"Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol\u20082005; 23: 965\u201372.","DOI":"10.1200\/JCO.2005.06.124"},{"key":"2022061701492614700_B23","unstructured":"Lotem J, Sachs L. Control of apoptosis in hematopoiesis and leukemia by cytokines, tumor suppressor and oncogenes. Leukemia\u20081996; 10: 925\u201331."},{"key":"2022061701492614700_B24","doi-asserted-by":"crossref","unstructured":"Zhang W, Konopleva M, Ruvolo VR, et al. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia\u20082008; 22: 808\u201318.","DOI":"10.1038\/sj.leu.2405098"},{"key":"2022061701492614700_B25","doi-asserted-by":"crossref","unstructured":"Horita M, Andreu EJ, Benito A, et al. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med\u20082000; 191: 977\u201384.","DOI":"10.1084\/jem.191.6.977"},{"key":"2022061701492614700_B26","doi-asserted-by":"crossref","unstructured":"Jane EP, Premkumar DR, Pollack IF. Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells. J Pharmacol Exp Ther\u20082006; 319: 1070\u201380.","DOI":"10.1124\/jpet.106.108621"},{"key":"2022061701492614700_B27","doi-asserted-by":"crossref","unstructured":"Yu C, Friday BB, Lai JP, et al. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol Cancer Ther\u20082006; 5: 2378\u201387.","DOI":"10.1158\/1535-7163.MCT-06-0235"},{"key":"2022061701492614700_B28","doi-asserted-by":"crossref","unstructured":"Dasmahapatra G, Yerram N, Dai Y, Dent P, Grant S. Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation. Clin Cancer Res\u20082007; 13: 4280\u201390.","DOI":"10.1158\/1078-0432.CCR-07-0835"},{"key":"2022061701492614700_B29","doi-asserted-by":"crossref","unstructured":"Hideshima T, Podar K, Chauhan D, et al. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene\u20082004; 23: 8766\u201376.","DOI":"10.1038\/sj.onc.1208118"},{"key":"2022061701492614700_B30","doi-asserted-by":"crossref","unstructured":"Guida T, Anaganti S, Provitera L, et al. Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor \u03b2 gatekeeper mutants. Clin Cancer Res\u20082007; 13: 3363\u20139.","DOI":"10.1158\/1078-0432.CCR-06-2667"},{"key":"2022061701492614700_B31","doi-asserted-by":"crossref","unstructured":"Guo T, Agaram NP, Wong GC, et al. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res\u20082007; 13: 4874\u201381.","DOI":"10.1158\/1078-0432.CCR-07-0484"},{"key":"2022061701492614700_B32","doi-asserted-by":"crossref","unstructured":"Lierman E, Folens C, Stover EH, et al. Sorafenib is a potent inhibitor of FIP1L1-PDGFR\u03b1 and the imatinib-resistant FIP1L1-PDGFR\u03b1 T674I mutant. Blood\u20082006; 108: 1374\u20136.","DOI":"10.1182\/blood-2006-02-004457"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/69\/9\/3927\/2624571\/3927.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/69\/9\/3927\/2624571\/3927.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T09:28:12Z","timestamp":1655458092000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/69\/9\/3927\/553398\/Sorafenib-Induces-Apoptosis-Specifically-in-Cells"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,30]]},"references-count":32,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2009,4,30]]},"published-print":{"date-parts":[[2009,5,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-08-2978","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,30]]}}}